Announcements Trials
Browse Landscape

Phase

Phase 2 87Phase 3 43Phase 1/2 9Phase 1 9Phase NA 2Phase 4 2Phase 2/3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 1Facies 1Carcinoma, Basal Cell 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Interferon-alpha × Clear all
NCT02027064 2016-09-29

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Peking University People's Hospital

Phase 4 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00581425 2013-01-25

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

Phase 4 Completed
49 enrolled
Dermatologic

Carcinoma, Basal Cell, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡